Press Releases

• Asimov: Completes Lead Optimization Campaign with Mabylon AG to Advance Trispecific Antibody for Tree Pollen Allergies More
• Cure Alzheimer’s Fund: Presents the 2026 Jeffrey L. Morby Prize for Exceptional Research More
• Dana-Farber Cancer Institute: RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study More
• enGene: Updated Interim Results From LEGEND Pivotal Cohort More
• Entrada Therapeutics: Positive Topline Results From Cohort 1 of Participants With Duchenne Muscular Dystrophy Treated With ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study More
• Ernexa Therapeutics: Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models More
• Moderna: New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 More
• Nona Biosciences: Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation More
• Parabilis Medicines: Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors More
• Partner Therapeutics: Receipt of FDA Commissioner's National Priority Voucher for BIZENGRI (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma More
• Ukko: First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment More

Financial News

• Amylyx Pharmaceuticals: First Quarter 2026 Financial Results More
• BeOne Culls Five Cancer Programs and an Autoimmune Phase 2 More*
• Black Diamond Therapeutics: First Quarter 2026 Financial Results and Provides Corporate Update More
• Blackstone Life Sciences: Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency More
• Charles River Laboratories: First-Quarter 2026 Results More
• Climb Bio: First Quarter 2026 Financial Results and Provides Business Updates More
• Collegium: First Quarter 2026 Financial Results and Highlights Recent Company Progress More
• Cullinan Therapeutics: Corporate Update and Reports First Quarter 2026 Financial Results More
• Entrada Therapeutics: First Quarter 2026 Financial Results More
• Foghorn Therapeutics: First Quarter 2026 Financial and Corporate Update More
• Generate Biomedicines: First Quarter 2026 Financial Results and Provides Business Update More
• Ironwood Pharmaceuticals: Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance More
• Korro: First Quarter 2026 Financial Results and Provides Corporate Update More
• Monte Rosa Therapeutics: First Quarter 2026 Financial Results and Business Updates More
• More on CellCentric Raising $220m to Advance Myeloma Drug More*
• More on German Reimbursement Deal for Vertex’ Casgevy More*
• Neumora Therapeutics: First Quarter 2026 Financial Results and Provides Business Update More
• Nuvalent: Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results More
• Praxis Precision Medicines: Corporate Update and Reports First Quarter 2026 Financial Results More
• Quanterix: Financial Results for the First Quarter of 2026 More
• Rapport Therapeutics: First Quarter 2026 Financials and Provides Business Update More
• Sarepta Therapeutics: First Quarter 2026 Financial Results and Recent Corporate Developments More
• Scholar Rock: First Quarter 2026 Financial Results and Recent Business Highlights More
• Vericel: First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance More
• Viridian Therapeutics: Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million More
• Zai Lab: First Quarter 2026 Financial Results and Recent Corporate Updates More
• Zevra: First Quarter 2026 Financial Results and Corporate Update More

Media/Misc Coverage

• Alnylam Rebuked by FDA Over Efficacy Claims on Amvuttra Website More
  
• Oncodesign Services Extends Collaboration With GIP ARRONAX to Strengthen Astatine-211 Supply for Targeted Alpha Radiotherapy. More
  
• Subscribe to LifeSci Startup for Updates on US Startups More

Career Center

• AI in Biotech: The New Frontier for Leadership & Strategy More
• CollectiveMinds: The First Slide Investors Study Isn‘t the Science — It’s the Team More
• Empowering Students Through STEM: A Conversation With Massachusetts Science & Engineering Fair Executive Director Helen Rosenfeld More
  
• From Seed to Series C: What Investors Look for Beyond the Science More
• M&A in Life Sciences: The Turning Tide – Why Now is a Strategic Inflection for Biopharma and Biotech More
• More Than Executive Search: Building Leadership for Every Stage of Growth More
• Pfizer’s Strategy Chief Andrew Baum Steps Down; Helus Pharma Swaps Out CEO After Two Months More*
• Telling Your Science Story to Investors More

• SynBioBeta 2026 May 4-7
  
• AAPS National Biotechnology Conference May 11-14
  
• ASGCT Annual Meeting May 11-15
• Bio-IT World Conference & Expo May 19-21
• Modernizing Mouse Colony Management: Where the 3Rs and Performance Meet May 20
• Boston Life Sciences Conference June 2
  
• Better Together: A Pharma & Biotech EHS Forum June 3
• NYC AI x Longevity Summit June 4-5
• DIA 2026 Global Annual Meeting June 14-18
• Bay Area Life Sciences & Biotech Conference June 17
  
• 2026 SoCal TBA 10th Anniversary Symposium| AI, Biotech & VC at UCLA June 21
  
• BIO 2026 June 22-25
• Global Biotech CEO Summit July 13-15
• ADLM Annual Meeting July 26-30

Companies

Boston Sponsors